Market Research Logo

Influenzavirus B Infections - Pipeline Review, H2 2018

Influenzavirus B Infections - Pipeline Review, H2 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Influenzavirus B Infections - Pipeline Review, H2 2018, provides an overview of the Influenzavirus B Infections (Infectious Disease) pipeline landscape.

Type B influenza is a subtype of the influenza virus that tends to occur sporadically. Symptoms include runny nose, sore throat, aching muscles, malaise, watery eyes, aching body, loss of appetite and weakness. Treatment includes antiviral, analgesics and antipyretics medications.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Influenzavirus B Infections - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Influenzavirus B Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Influenzavirus B Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Influenzavirus B Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 6, 11, 3, 1, 13 and 5 respectively. Similarly, the Universities portfolio in Phase III and Discovery stages comprises 3 and 1 molecules, respectively.

Influenzavirus B Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Influenzavirus B Infections (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Influenzavirus B Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Influenzavirus B Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Influenzavirus B Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Influenzavirus B Infections (Infectious Disease)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Influenzavirus B Infections (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Influenzavirus B Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.


Introduction
Influenzavirus B Infections - Overview
Influenzavirus B Infections - Therapeutics Development
Influenzavirus B Infections - Therapeutics Assessment
Influenzavirus B Infections - Companies Involved in Therapeutics Development
Influenzavirus B Infections - Drug Profiles
Influenzavirus B Infections - Dormant Projects
Influenzavirus B Infections - Discontinued Products
Influenzavirus B Infections - Product Development Milestones
Appendix
List of Tables
Number of Products under Development for Influenzavirus B Infections, H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products under Development by Companies, H2 2018 (Contd..1), H2 2018
Number of Products under Development by Universities/Institutes, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018 (Contd..1), H2 2018
Products under Development by Companies, H2 2018 (Contd..2), H2 2018
Products under Development by Universities/Institutes, H2 2018
Number of Products by Stage and Target, H2 2018
Number of Products by Stage and Mechanism of Action, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Influenzavirus B Infections - Pipeline by AbbVie Inc, H2 2018
Influenzavirus B Infections - Pipeline by Adimmune Corp, H2 2018
Influenzavirus B Infections - Pipeline by Altravax Inc, H2 2018
Influenzavirus B Infections - Pipeline by Amarillo Biosciences Inc, H2 2018
Influenzavirus B Infections - Pipeline by Aphios Corp, H2 2018
Influenzavirus B Infections - Pipeline by AstraZeneca Plc, H2 2018
Influenzavirus B Infections - Pipeline by AusBio Ltd, H2 2018
Influenzavirus B Infections - Pipeline by Biotron Ltd, H2 2018
Influenzavirus B Infections - Pipeline by Cocrystal Pharma Inc, H2 2018
Influenzavirus B Infections - Pipeline by ContraFect Corp, H2 2018
Influenzavirus B Infections - Pipeline by Daiichi Sankyo Co Ltd, H2 2018
Influenzavirus B Infections - Pipeline by e-Therapeutics Plc, H2 2018
Influenzavirus B Infections - Pipeline by Evotec AG, H2 2018
Influenzavirus B Infections - Pipeline by GC Pharma, H2 2018
Influenzavirus B Infections - Pipeline by GlaxoSmithKline Plc, H2 2018
Influenzavirus B Infections - Pipeline by Inovio Pharmaceuticals Inc, H2 2018
Influenzavirus B Infections - Pipeline by Kineta Inc, H2 2018
Influenzavirus B Infections - Pipeline by Medicago Inc, H2 2018
Influenzavirus B Infections - Pipeline by MedImmune LLC, H2 2018
Influenzavirus B Infections - Pipeline by Novavax Inc, H2 2018
Influenzavirus B Infections - Pipeline by Romark Laboratories LC, H2 2018
Influenzavirus B Infections - Pipeline by Sanofi, H2 2018
Influenzavirus B Infections - Pipeline by Sanofi Pasteur SA, H2 2018
Influenzavirus B Infections - Pipeline by Seqirus Ltd, H2 2018
Influenzavirus B Infections - Pipeline by Shionogi & Co Ltd, H2 2018
Influenzavirus B Infections - Pipeline by Sinovac Biotech Ltd, H2 2018
Influenzavirus B Infections - Pipeline by Therapeutic Systems Research Laboratories Inc, H2 2018
Influenzavirus B Infections - Pipeline by Toyama Chemical Co Ltd, H2 2018
Influenzavirus B Infections - Pipeline by Vaxart Inc, H2 2018
Influenzavirus B Infections - Dormant Projects, H2 2018
Influenzavirus B Infections - Dormant Projects, H2 2018 (Contd..1), H2 2018
Influenzavirus B Infections - Discontinued Products, H2 2018
List of Figures
Number of Products under Development for Influenzavirus B Infections, H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products under Development by Universities/Institutes, H2 2018
Number of Products by Top 10 Targets, H2 2018
Number of Products by Stage and Top 10 Targets, H2 2018
Number of Products by Mechanism of Actions, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Molecule Types, H2 2018
Number of Products by Stage and Molecule Types, H2 2018

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report